As of May 27, 2025, Fine Foods & Pharmaceuticals NTM SpA (FF.MI) reports a EV/EBITDA of 4.96.
EV/EBITDA evaluates a company's total value relative to its earnings before interest, taxes, depreciation, and amortization, useful for comparing firms with different capital structures.
Comparing Fine Foods & Pharmaceuticals NTM SpA's EV/EBITDA to Peers
To better understand Fine Foods & Pharmaceuticals NTM SpA's position, it's useful to compare its EV/EBITDA against industry peers. Below are selected comparisons:
| Company | EV/EBITDA |
|---|---|
| Fine Foods & Pharmaceuticals NTM SpA (FF.MI) | 4.96 |
| Pangaea Oncology SA (PANG.MC) | 73.35 |
| International Isotopes Inc (INIS) | 50.39 |
| Lonza Group AG (LONN.SW) | 39.89 |
| Chemometec A/S (CHEMM.CO) | 37.59 |
| Sartorius Stedim Biotech SA (DIM.PA) | 29.29 |
Compared to its competitors, Fine Foods & Pharmaceuticals NTM SpA's EV/EBITDA is about average compared to peers, indicating market valuation in line with industry expectations.